Polypharmacology of Approved Anticancer Drugs.

Autor:	Amelio I; Medical Research Council Toxicology Unit, Leicester LE1 9HN, United Kingdom., Lisitsa A; Institute of Biomedical Chemistry of the Russian Academy of Medical Sciences, Pogodinskaya Street, Moscow, Russian Federation., Knight RA; Medical Research Council Toxicology Unit, Leicester LE1 9HN, United Kingdom., Melino G; Institute of Cytology, Saint-Petersburg 194064, Russian Federation., Antonov AV; Medical Research Council Toxicology Unit, Leicester LE1 9HN, United Kingdom.
Jazyk:	angličtina
Zdroj:	Current drug targets [Curr Drug Targets] 2017; Vol. 18 (5), pp. 534-543.
DOI:	10.2174/1389450117666160301095233
Abstrakt:	The major drug discovery efforts in oncology have been concentrated on the development of selective molecules that are supposed to act specifically on one anticancer mechanism by modulating a single or several closely related drug targets. However, a bird's eye view on data from multiple available bioassays implies that most approved anticancer agents do, in fact, target many more proteins with different functions. Here we will review and systematize currently available information on the targets of several anticancer drugs along with revision of their potential mechanisms of action. Polypharmacology of the current antineoplastic agents suggests that drug clinical efficacy in oncology can be achieved only via modulation of multiple cellular mechanisms. (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu